Praxis Precision Medicines Sees 20% Surge on Positive Interim EMBOLD Trial Data

Praxis Precision Medicines' shares surged 20% in premarket trading after a Data Monitoring Committee recommended early stopping of the EMBOLD trial of Relutrigine based on interim efficacy results. The company plans to share topline results at the American Epilepsy Society Annual Meeting on December 6, 2025. The FDA meeting and NDA filing timing will be decided after the meeting. The stock closed yesterday at $189.97, up 2.05%, and is trading 23.18% higher at $234 in the pre-market.